Peter W. PENG, Author at MediaMedic

IDweek2023 | Optimizing Neonatal UTI Management: Weighing IV and Oral Therapies

By Peter W. PENG 2023.10.26

IDweek 2023 Optimizing Neonatal UTI Management: Weighing IV and Oral Therapies Neonatal urinary tract infections (UTIs) present a significant challenge in pediatric infectious diseases, with an ongoing debate among healthcare professionals about the best approach for managing neonates with bacteremic UTIs. This article provides a comprehensive examination of the key considerations when it comes to neonatal UTI treatment, focusing on the pros and cons of intravenous (IV) and oral therapy options.

IDweek2023 | Navigating the Future of Healthcare: A Comprehensive Exploration of the Intersection of Artificial Intelligence and Medicine

By Peter W. PENG 2023.10.26

IDweek2023 Navigating the Future of Healthcare: A Comprehensive Exploration of the Intersection of Artificial Intelligence and Medicine The world stands on the precipice of a technological revolution as the advent of Artificial Intelligence (AI) ushers in a new era of possibilities across various sectors. One of the most significant beneficiaries of this revolution is healthcare, a sector that is ripe for transformative change. The potential of AI to revolutionize healthcare is not just a promising proposition, but an unfolding reality. However, the path to fully integrating AI into healthcare is not without challenges. It is crucial to navigate these hurdles carefully as we move towards a future where AI and healthcare work in harmony to enhance the health outcomes of individuals and communities at large.

IDweek 2023 | A Celebration of Achievements and a Look Towards the Future of Infectious Diseases

By Peter W. PENG 2023.10.26

ID Week 2023 was an exceptional gathering of professionals dedicated to the field of infectious diseases. The event served as a platform for celebrating past achievements, addressing present challenges, and…

Interview with Dr. Girard Deciphers at ELCC 2023

By Peter W. PENG 2023.10.24

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.

Interview with Minggui Wang at ECCMID 2023

By Peter W. PENG 2023.10.23

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) recently took place in Copenhagen, Denmark, drawing attention as one of the first major in-person events since the easing of the COVID-19 pandemic. The event, a hallmark in the world of infectious diseases and clinical microbiology, attracted numerous participants, among whom was Dr. Minggui Wang, the director of the Institute of Antibiotics, Huashan Hospital, Fudan University. Dr. Wang shared insights on the advances and experiences at the conference, with a particular focus on fungal infections.

Dr. Michelle Seif: CAR-T Therapy’s Potential in Treating Fungal Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), the prospect of utilizing Chimeric Antigen Receptor T-cells (CAR-T) for medical treatments has emerged as a promising avenue, especially in the realm of infectious diseases. Notably, Dr. Michelle Seif from the University Hospital Würzburg, Germany, has presented new findings that expand upon the potential use of CAR-T therapy in fungal infections.

Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

By Peter W. PENG 2023.10.23

In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was Dr. José Luis Del Pozo from the University of Navarra. Infectious Disease Frontline had a chance to sit down with him for a comprehensive discussion.

Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

By Peter W. PENG 2023.10.23

Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the past, present, and future of AST.

Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

By Peter W. PENG 2023.10.23

Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue, with Dr. Anne J. Gonzales-Luna from the University of Houston College of Pharmacy offering her expertise.

Youth Forum of APACC 2023 | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART

By Peter W. PENG 2023.10.23

Hello everyone, I'm Xiaosheng Liu , a graduate student from Professor Taisheng Li's team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I'm delighted to participate in this year's APACC conference (2023) and present two poster studies conducted by our team at the conference. APACC is the most cutting-edge and top academic conference in the Asia-Pacific region for HIV/AIDS, and I hope to broaden my knowledge in various aspects through this conference.